Literature DB >> 16376282

Immunoglobulin for concurrent Guillain-Barré and immune thrombocytopenic purpura.

Lawrence A Zeidman1, Christopher D Fahey, David L Grinblatt, Krisztina Harsanyi.   

Abstract

Guillain-Barré syndrome, or acute inflammatory demyelinating polyradiculoneuropathy, and immune thrombocytopenic purpura are both autoimmune disorders thought to result from molecular mimicry in response to an antecedent introduction of foreign antigen. Guillain-Barré syndrome is an ascending motor paralysis that can lead to respiratory compromise. Immune thrombocytopenic purpura is an isolated disorder of platelet destruction leading to mucocutaneous bleeding. Guillain-Barré does not typically occur with other autoimmune disorders, and concurrent Guillain-Barré and immune thrombocytopenic purpura has only rarely been reported. We present a patient with both conditions who experienced prompt resolution of neurologic and hematologic sequelae after intravenous immunoglobulin therapy was initiated within 12 hours of presentation. The case provides further evidence that Guillain-Barré syndrome and immune thrombocytopenic purpura can occur simultaneously, possibly caused by a similar pathogenic mechanism, as well as suggesting that the prompt initiation of intravenous immunoglobulin is an effective monotherapy leading to prompt resolution of both conditions and prevention of further sequelae.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16376282     DOI: 10.1016/j.pediatrneurol.2005.06.012

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  1 in total

1.  Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?

Authors:  Raquel Jaso; María Sierra; Jesús Calleja; Carmen Valero; Julio Pascual
Journal:  J Neurol       Date:  2009-11-22       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.